ICER releases draft evidence report on therapies for sickle cell disease

23 January 2020 - ICER’s ongoing assessment emphasises that policy makers will need to consider, in addition to traditional measures ...

Read more →

Health Technology Assessment around the world: broadening the understanding of cross-country differences

22 January 2020 - Value in Health, the official journal of ISPOR—the professional society for health economics and outcomes research, ...

Read more →

Reimbursement for Repatha to expand treatment options for ASCVD patients

22 January 2020 - Amgen is set to expand treatment options for atherosclerotic cardiovascular disease patients with Repatha, a high-cholesterol treatment, ...

Read more →

NHS patients denied new lung cancer drug after another NICE deadlock

22 January 2020 - Certain untreated lung cancer patients on England’s NHS will have to make do with older drugs ...

Read more →

NICE rejects Janssen’s Stelara on cost efficiency grounds

22 January 2020 - NICE has released a draft guidance not recommending Janssen’s Stelara (ustekinumab) for moderately to severely active ...

Read more →

After 20 years of using economic evaluation, should NICE be considered a methods innovator?

13 January 2020 - NICE is only one of several organisations internationally that uses economic evaluation as part of decision ...

Read more →

Closing the cycle of innovation in health care in Europe

17 January 2020 - Pragmatic or practice-oriented comparative effectiveness trials may be conducted to fill the evidence gaps that are revealed ...

Read more →

Use of patient preference studies in HTA decision making: a NICE perspective

16 January 2020 - Patient preference studies could provide valuable insights to a National Institute for Health and Care Excellence committee ...

Read more →

NICE encourages further data collection on ‘game changing’ histology independent cancer drugs

17 January 2020 - Larotrectinib (also called Vitrakvi and made by Bayer), a new treatment for a range of cancers, can’t ...

Read more →

Asfotase alfa in hypophosphatasia in children and adolescents: survival advantage for small children

15 January 2020 - Weak evidence does not allow a specific statement to be made about the extent of the added ...

Read more →

NICE ‘OK’ for Lynparza

16 January 2020 - NICE has recommended MSD and AstraZeneca’s Lynparza (olaparib) tablets, for adults who have relapsed platinum-sensitive ovarian, ...

Read more →

Breast cancer patients to have further NICE approved drug combination option on Cancer Drugs Fund

15 January 2020 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on ...

Read more →

Larotrectinib in tumours with NTRK gene fusion: data are not yet sufficient for derivation of an added benefit

15 January 2020 - First assessment of a histology-independent drug/studies without control arms. ...

Read more →

Differences in health technology assessment recommendations among European jurisdictions: the role of practice variations

14 January 2020 - HTA recommendations vary widely throughout Europe, even for the same medicine. ...

Read more →

NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata

15 January 2020 - Cost-effectiveness watchdog issues a round of draft and final guidance. ...

Read more →